Prostate Cancer
Biochemical-markers for the diagnosis of bone metastasis: A review in clinical - Abstract
April 29, 2011
Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape - Abstract
April 29, 2011
Barriers and facilitators to digital rectal examination screening among African-American and African-Caribbean men - Abstract
April 29, 2011
Internal fiducial markers and susceptibility effects in MRI-simulation and measurement of spatial accuracy - Abstract
April 29, 2011
FDA approves Zytiga for late-stage prostate cancer
April 29, 2011
Listening to Provenge - what a costly cancer treatment says about future Medicare policy - Abstract
April 28, 2011
Practical method of adaptive radiotherapy for prostate cancer using real-time electromagnetic tracking - Abstract
April 28, 2011
Comparison of High-Dose Proton Radiotherapy and Brachytherapy in Localized Prostate Cancer: A Case-Matched Analysis - Abstract
April 28, 2011
Daily online bony correction is required for prostate patients without fiducial markers or soft-tissue imaging - Abstract
April 28, 2011
Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1 - Abstract
April 28, 2011
EAU 2011 - A negative multi-parametric MRI can rule out up to 97% of clinically significant prostate cancer - Session Highlights
April 28, 2011